Published in Diabetes Care on September 09, 2009
Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA (2013) 3.65
Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes (2010) 2.94
Early window of diabetes determinism in NOD mice, dependent on the complement receptor CRIg, identified by noninvasive imaging. Nat Immunol (2012) 2.11
Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: diabetes autoimmunity study in the young. Diabetes Care (2011) 1.86
Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes (2011) 1.77
Network for Pancreatic Organ Donors with Diabetes (nPOD): developing a tissue biobank for type 1 diabetes. Diabetes Metab Res Rev (2012) 1.68
Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol (2013) 1.65
Distinguishing persistent insulin autoantibodies with differential risk: nonradioactive bivalent proinsulin/insulin autoantibody assay. Diabetes (2011) 1.53
The Juvenile Diabetes Research Foundation Network for Pancreatic Organ Donors with Diabetes (nPOD) Program: goals, operational model and emerging findings. Pediatr Diabetes (2013) 1.46
Vaccination against type 1 diabetes. J Intern Med (2011) 1.46
Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. Diabetes Care (2012) 1.45
Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care (2015) 1.36
β cell death and dysfunction during type 1 diabetes development in at-risk individuals. J Clin Invest (2015) 1.31
The pathogenesis and natural history of type 1 diabetes. Cold Spring Harb Perspect Med (2012) 1.30
The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care (2013) 1.23
The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia (2015) 1.20
Evidence that HLA class I and II associations with type 1 diabetes, autoantibodies to GAD and autoantibodies to IA-2, are distinct. Diabetes (2011) 1.20
GAD65 autoantibodies detected by electrochemiluminescence assay identify high risk for type 1 diabetes. Diabetes (2013) 1.19
Proinsulin/Insulin autoantibodies measured with electrochemiluminescent assay are the earliest indicator of prediabetic islet autoimmunity. Diabetes Care (2013) 1.11
Accelerated progression from islet autoimmunity to diabetes is causing the escalating incidence of type 1 diabetes in young children. J Autoimmun (2011) 1.04
The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes. Diabetes Care (2012) 1.03
Immune therapy in type 1 diabetes mellitus. Nat Rev Endocrinol (2013) 1.02
Islet autoantigens: structure, function, localization, and regulation. Cold Spring Harb Perspect Med (2012) 1.02
Effects of non-HLA gene polymorphisms on development of islet autoimmunity and type 1 diabetes in a population with high-risk HLA-DR,DQ genotypes. Diabetes (2012) 1.01
Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading. J Autoimmun (2012) 1.01
Role of Type 1 Diabetes-Associated SNPs on Risk of Autoantibody Positivity in the TEDDY Study. Diabetes (2014) 1.01
Predictors of Progression From the Appearance of Islet Autoantibodies to Early Childhood Diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY). Diabetes Care (2015) 1.01
Predicting adult-onset autoimmune diabetes: clarity from complexity. Diabetes (2010) 0.97
Electrochemiluminescence assays for insulin and glutamic acid decarboxylase autoantibodies improve prediction of type 1 diabetes risk. Diabetes Technol Ther (2015) 0.97
Zinc transporter 8 and MAP3865c homologous epitopes are recognized at T1D onset in Sardinian children. PLoS One (2013) 0.94
Immune Regulation in T1D and T2D: Prospective Role of Foxp3+ Treg Cells in Disease Pathogenesis and Treatment. Front Endocrinol (Lausanne) (2013) 0.93
New insight on human type 1 diabetes biology: nPOD and nPOD-transplantation. Curr Diab Rep (2014) 0.93
Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants. Diabetes (2013) 0.93
The benefits of using genetic information to design prevention trials. Am J Hum Genet (2013) 0.91
Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report. Diabetes Care (2015) 0.91
Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes (2016) 0.88
Extrapancreatic autoantibody profiles in type I diabetes. PLoS One (2012) 0.88
Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective and age-independent strategy to identify rapid progressors to clinical onset among relatives of type 1 diabetic patients. Clin Exp Immunol (2013) 0.88
Thyroid profile and autoantibodies in Type 1 diabetes subjects: A perspective from Eastern India. Indian J Endocrinol Metab (2017) 0.88
Predictors of slow progression to diabetes in children with multiple islet autoantibodies. J Autoimmun (2016) 0.87
Established and emerging biomarkers for the prediction of type 1 diabetes: a systematic review. Transl Res (2014) 0.87
CD4+ T cells recognize diverse epitopes within GAD65: implications for repertoire development and diabetes monitoring. Immunology (2013) 0.87
The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes. Diabetologia (2015) 0.86
T cell epitopes and post-translationally modified epitopes in type 1 diabetes. Curr Diab Rep (2015) 0.86
Immunologic and metabolic biomarkers of β-cell destruction in the diagnosis of type 1 diabetes. Cold Spring Harb Perspect Med (2012) 0.85
Improving prediction of type 1 diabetes by testing non-HLA genetic variants in addition to HLA markers. Pediatr Diabetes (2013) 0.85
Reversion of β-Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study. Diabetes Care (2016) 0.84
A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants. Diabetes Care (2011) 0.84
ECL-IAA and ECL-GADA Can Identify High-Risk Single Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study. Diabetes Technol Ther (2016) 0.83
Type 1 diabetes and polyglandular autoimmune syndrome: A review. World J Diabetes (2015) 0.82
Introduction. Diabetes Care (2015) 0.82
Prediction and prevention of type 1 diabetes: update on success of prediction and struggles at prevention. Pediatr Diabetes (2015) 0.81
The Use of Electrochemiluminescence Assays to Predict Autoantibody and Glycemic Progression Toward Type 1 Diabetes in Individuals with Single Autoantibodies. Diabetes Technol Ther (2017) 0.80
Characteristics of in-vitro phenotypes of glutamic acid decarboxylase 65 autoantibodies in high-titre individuals. Clin Exp Immunol (2013) 0.79
Etiopathogenesis of insulin autoimmunity. Anat Res Int (2012) 0.79
Serum titres of anti-glutamic acid decarboxylase-65 and anti-IA-2 autoantibodies are associated with different immunoregulatory milieu in newly diagnosed type 1 diabetes patients. Clin Exp Immunol (2012) 0.79
The development, validation, and utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS). Curr Diab Rep (2015) 0.78
Mobilization without immune depletion fails to restore immunological tolerance or preserve beta cell function in recent onset type 1 diabetes. Clin Exp Immunol (2015) 0.78
Metabolic abnormalities in the pathogenesis of type 1 diabetes. Curr Diab Rep (2014) 0.78
Novel biomarkers in type 1 diabetes. Rev Diabet Stud (2012) 0.78
Prognostic Classification Factors Associated With Development of Multiple Autoantibodies, Dysglycemia, and Type 1 Diabetes-A Recursive Partitioning Analysis. Diabetes Care (2016) 0.78
Roles of Commensal Microbiota in Pancreas Homeostasis and Pancreatic Pathologies. J Diabetes Res (2015) 0.77
Regulation of B lymphocyte responses to Toll-like receptor ligand binding during diabetes prevention in non-obese diabetic (NOD) mice. J Diabetes (2015) 0.77
Validation of a rapid type 1 diabetes autoantibody screening assay for community-based screening of organ donors to identify subjects at increased risk for the disease. Clin Exp Immunol (2016) 0.77
Comprehensive biomarker testing of glycemia, insulin resistance, and beta cell function has greater sensitivity to detect diabetes risk than fasting glucose and HbA1c and is associated with improved glycemic control in clinical practice. J Cardiovasc Transl Res (2014) 0.77
Staging the progression to type 1 diabetes with prediagnostic markers. Curr Opin Endocrinol Diabetes Obes (2016) 0.77
Targeted immune interventions for type 1 diabetes: not as easy as it looks! Curr Opin Endocrinol Diabetes Obes (2014) 0.77
Role of Type 1 Diabetes-Associated SNPs on Autoantibody Positivity in the Type 1 Diabetes Genetics Consortium: Overview. Diabetes Care (2015) 0.76
Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons. Islets (2013) 0.76
Non-HLA type 1 diabetes genes modulate disease risk together with HLA-DQ and islet autoantibodies. Genes Immun (2015) 0.76
Plant-based vaccines for oral delivery of type 1 diabetes-related autoantigens: Evaluating oral tolerance mechanisms and disease prevention in NOD mice. Sci Rep (2017) 0.75
Positive evidence for vitamin A role in prevention of type 1 diabetes. World J Diabetes (2016) 0.75
Anti-Insulin Immune Responses Are Detectable in Dogs with Spontaneous Diabetes. PLoS One (2016) 0.75
Role of immune system modulation in prevention of type 1 diabetes mellitus. Indian J Endocrinol Metab (2012) 0.75
Prevention of Type 1 Diabetes Mellitus using a Novel Vaccine. Ther Adv Endocrinol Metab (2011) 0.75
Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects? Diabetes Care (2016) 0.75
Diagnosis of insulin autoimmune syndrome using polyethylene glycol precipitation and gel filtration chromatography with ex vivo insulin exchange. Clin Endocrinol (Oxf) (2016) 0.75
Heterogeneity of B Cell Functions in Stroke-Related Risk, Prevention, Injury, and Repair. Neurotherapeutics (2016) 0.75
Utility of diabetes-associated autoantibodies for classification of new onset diabetes in children and adolescents. Pediatr Diabetes (2015) 0.75
Antibodies to post-translationally modified insulin as a novel biomarker for prediction of type 1 diabetes in children. Diabetologia (2017) 0.75
The Influence of Type 1 Diabetes Genetic Susceptibility Regions, Age, Sex, and Family History to the Progression from Multiple Autoantibodies to Type 1 Diabetes: A TEDDY Study Report. Diabetes (2017) 0.75
Impact of age and antibody type on progression from single to multiple autoantibodies in type 1 diabetes relatives. J Clin Endocrinol Metab (2017) 0.75
B cells in type 1 diabetes mellitus and diabetic kidney disease. Nat Rev Nephrol (2017) 0.75
Increased Effector Memory Insulin-Specific CD4(+)T-cells Correlate with Insulin Autoantibodies in Recent-Onset Type 1 Diabetic Patients. Diabetes (2017) 0.75
Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med (2002) 7.00
Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet (1974) 5.59
Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care (2005) 5.04
Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science (1983) 4.16
Antiislet autoantibodies usually develop sequentially rather than simultaneously. J Clin Endocrinol Metab (1996) 2.78
Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes (2004) 2.74
Evidence for a long prediabetic period in type I (insulin-dependent) diabetes mellitus. Lancet (1982) 2.43
Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest (2004) 2.34
Islet-cell antibodies in diabetes mellitus. Lancet (1976) 2.20
Antibodies to a 64,000 Mr human islet cell antigen precede the clinical onset of insulin-dependent diabetes. J Clin Invest (1987) 2.09
A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia (1994) 2.03
Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia (2009) 2.00
Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes. A population-based study. The Childhood Diabetes in Finland Study Group. J Clin Invest (1998) 1.91
A novel micro-assay for insulin autoantibodies. J Autoimmun (1997) 1.90
Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes (1994) 1.82
Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun (1996) 1.68
Cytoplasmic islet cell antibodies remain valuable in defining risk of progression to type 1 diabetes in subjects with other islet autoantibodies. Pediatr Diabetes (2005) 1.64
Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia (2006) 1.60
Relationship of the 37,000- and 40,000-M(r) tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). J Clin Invest (1995) 1.60
Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes. J Clin Endocrinol Metab (2003) 1.55
Value of insulin autoantibodies as serum markers for insulin-dependent diabetes mellitus. Lancet (1985) 1.38
Distinct antibody specificities to a 64-kD islet cell antigen in type 1 diabetes as revealed by trypsin treatment. J Exp Med (1990) 1.36
Relationship of beta-cell function and autoantibodies to progression and nonprogression of subclinical type 1 diabetes: follow-up of the Seattle Family Study. Diabetes (1999) 1.26
Autoantibodies to IA-2beta improve diabetes risk assessment in high-risk relatives. Diabetologia (2008) 1.25
International trial of the Edmonton protocol for islet transplantation. N Engl J Med (2006) 13.43
Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care (2005) 7.81
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med (2009) 6.89
Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med (2011) 6.74
The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A (2007) 6.44
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer (2005) 5.57
Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature (2005) 5.39
Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature (2010) 5.16
Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care (2005) 5.04
C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes (2004) 4.44
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet (2011) 4.30
Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Arch Intern Med (2007) 3.58
Diabetic somatic neuropathies. Diabetes Care (2004) 3.39
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet (2011) 3.13
Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes (2012) 3.11
Toward defining the autoimmune microbiome for type 1 diabetes. ISME J (2010) 3.03
O-mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding. Science (2010) 2.98
Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes (2010) 2.94
Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol Genet Metab (2008) 2.90
Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood (2009) 2.79
Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J Am Soc Nephrol (2008) 2.74
Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia. J Clin Endocrinol Metab (2010) 2.70
A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. Diabetes Care (2007) 2.67
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol (2014) 2.64
The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes (2008) 2.60
Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation (2011) 2.60
Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes. Diabetes Care (2010) 2.57
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood (2012) 2.51
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet (2013) 2.45
Diabetes care in the school and day care setting. Diabetes Care (2012) 2.41
Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med (2008) 2.29
Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice. Nat Med (2002) 2.29
IFIH1 polymorphisms are significantly associated with type 1 diabetes and IFIH1 gene expression in peripheral blood mononuclear cells. Hum Mol Genet (2008) 2.27
The impact of enhanced cleaning within the intensive care unit on contamination of the near-patient environment with hospital pathogens: a randomized crossover study in critical care units in two hospitals. Crit Care Med (2011) 2.23
Dystroglycan function requires xylosyl- and glucuronyltransferase activities of LARGE. Science (2012) 2.22
Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab (2004) 2.19
Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS One (2011) 2.18
Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care (2006) 2.15
A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes. Diabetes (2008) 2.09
Latent autoimmune diabetes in adults. J Clin Endocrinol Metab (2009) 2.04
Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care (2009) 2.02
No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes (2007) 1.99
A report on the International Transglutaminase Autoantibody Workshop for Celiac Disease. Am J Gastroenterol (2009) 1.94
Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J Clin Invest (2010) 1.93
Extreme genetic risk for type 1A diabetes. Proc Natl Acad Sci U S A (2006) 1.90
Innate immune collectin surfactant protein D simultaneously binds both neutrophil extracellular traps and carbohydrate ligands and promotes bacterial trapping. J Immunol (2011) 1.89
Genetic effects on age-dependent onset and islet cell autoantibody markers in type 1 diabetes. Diabetes (2002) 1.89
Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev (2004) 1.87
Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care (2007) 1.87
Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: diabetes autoimmunity study in the young. Diabetes Care (2011) 1.86
Deletion of Smad2 in mouse liver reveals novel functions in hepatocyte growth and differentiation. Mol Cell Biol (2006) 1.82
Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am J Hypertens (2009) 1.82
High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract (2009) 1.81
Culture-independent identification of gut bacteria correlated with the onset of diabetes in a rat model. ISME J (2009) 1.74
Lactobacillus johnsonii N6.2 mitigates the development of type 1 diabetes in BB-DP rats. PLoS One (2010) 1.70
Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med (2013) 1.69
Network for Pancreatic Organ Donors with Diabetes (nPOD): developing a tissue biobank for type 1 diabetes. Diabetes Metab Res Rev (2012) 1.68
Influence of fecal sample storage on bacterial community diversity. Open Microbiol J (2009) 1.68
Specificity and detection of insulin-reactive CD4+ T cells in type 1 diabetes in the nonobese diabetic (NOD) mouse. Proc Natl Acad Sci U S A (2011) 1.68
Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care (2008) 1.67
Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. Arterioscler Thromb Vasc Biol (2003) 1.65
IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. Proc Natl Acad Sci U S A (2011) 1.61
New features of disease after diagnosis in 6 forms of systemic vasculitis. J Rheumatol (2013) 1.59
Successful prospective prediction of type 1 diabetes in schoolchildren through multiple defined autoantibodies: an 8-year follow-up of the Washington State Diabetes Prediction Study. Diabetes Care (2002) 1.59
Use of SNOMED CT to represent clinical research data: a semantic characterization of data items on case report forms in vasculitis research. J Am Med Inform Assoc (2006) 1.57
SGK196 is a glycosylation-specific O-mannose kinase required for dystroglycan function. Science (2013) 1.57
Limitations in the cardiac risk reduction provided by coronary revascularization prior to elective vascular surgery. J Vasc Surg (2002) 1.56
Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes. J Clin Endocrinol Metab (2003) 1.55
Selection of patients for clinical trials: an interactive web-based system. Artif Intell Med (2004) 1.55